194 related articles for article (PubMed ID: 4809201)
41. Precursors of plasma triglyceride fatty acid in humans. Effects of glucose consumption, clofibrate administration, and alcoholic fatty liver.
Barter PJ; Nestel PJ; Carroll KF
Metabolism; 1972 Feb; 21(2):117-24. PubMed ID: 5009387
[No Abstract] [Full Text] [Related]
42. Long-term treatment of hyperlipidemic patients with clofibrate.
Berkowitz D
JAMA; 1971 Nov; 218(7):1002-5. PubMed ID: 5000568
[No Abstract] [Full Text] [Related]
43. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.
Schwartz EA; Koska J; Mullin MP; Syoufi I; Schwenke DC; Reaven PD
Atherosclerosis; 2010 Sep; 212(1):217-22. PubMed ID: 20557887
[TBL] [Abstract][Full Text] [Related]
44. Type V hyperlipoproteinaemia. Metabolic changes in hyperlipaemic and previously hyperlipaemic ("susceptible") male patients.
Jacobsen BB
Atherosclerosis; 1973; 17(3):471-81. PubMed ID: 4577010
[No Abstract] [Full Text] [Related]
45. Influence of triglyceridemia level on glucose tolerance and insulinemia in subjects with type IV hyperlipoproteinemia.
Debry G; Drouin P; Mejean L
Horm Metab Res; 1974 Sep; 6(5):421-2. PubMed ID: 4425070
[No Abstract] [Full Text] [Related]
46. [Normal behavior of glucose tolerance, insulin secretion and free fatty acids under carbohydrate load in childhood].
Amendt P; Michaelis D; Gottschling D; Hildmann W
Endokrinologie; 1974 Sep; 63(3):373-80. PubMed ID: 4470085
[No Abstract] [Full Text] [Related]
47. Lipid, glucose, and insulin interrelationships in normal, prediabetic, and chemical diabetic subjects.
Kyner JL; Levy RI; Soeldner JS; Gleason RE; Fredrickson DS
J Lab Clin Med; 1976 Sep; 88(3):345-58. PubMed ID: 956689
[TBL] [Abstract][Full Text] [Related]
48. [Potentiation by clofibride of the heparin-induced clearing reaction (intravascular hydrolysis of neutral lipids), in hyperlipemic rabbits].
Elsair J; Marquie G; Drif M; Khelfat K; Benouniche N; Tabet Aoul M; Tabet Aoul FS; Iklef F; Ghouini A
C R Seances Soc Biol Fil; 1982; 176(2):140-5. PubMed ID: 6212098
[TBL] [Abstract][Full Text] [Related]
49. [Stimulation of insulin secretion and hypoglycemia by medium chain triglyceride].
Ide H
Nihon Naika Gakkai Zasshi; 1971 Feb; 60(2):115-24. PubMed ID: 5103075
[No Abstract] [Full Text] [Related]
50. [Hypertriglyceridemia induced by carbohydrates in primary hyperlipoproteinemia].
Lussier-Cacan S; Beaudoin R; Gattereau A; Davignon J
Union Med Can; 1977 Apr; 106(4):474-84. PubMed ID: 860339
[No Abstract] [Full Text] [Related]
51. [The lipid reducing action of phenformin in primary type IV hyperlipoproteinaemia (author's transl)].
Lang PD; Vollmar J; Klemens UH; von Löwis P; Gries FA; Koschinsky T; Huth K; Pilz E; Schlierf G; Kremer GJ; Lenhart P; Schwandt P; Hammerl H; Studlar M
Dtsch Med Wochenschr; 1973 Nov; 98(48):2280-6. PubMed ID: 4762828
[No Abstract] [Full Text] [Related]
52. [Incidence of hyperlipoproteinemia and other risk factors in chronic and acute phases of patients with myocardial infarct].
Diehl HJ; Sorge F; Hoffmann H; Weidener J; Schloss W; Schwartzkopff W
Arzneimittelforschung; 1972 Oct; 22(10):1815-8. PubMed ID: 4678571
[No Abstract] [Full Text] [Related]
53. The identification of risk factors in normal children in the development of arteriosclerosis.
Drash A; Hengstenberg F
Ann Clin Lab Sci (1971); 1972; 2(5):348-59. PubMed ID: 5082977
[No Abstract] [Full Text] [Related]
54. 24-hour patterns of blood sugar, plasma insulin and free fatty acids in patients with primary endogenous hyperlipoproteinemia on isocaloric diets containing 30, 40 and 79 cal% carbohydrates.
Schellenberg B; Oster P; Vogel G; Heuck CC; Schlierf G
Nutr Metab; 1979; 23(4):316-26. PubMed ID: 220571
[TBL] [Abstract][Full Text] [Related]
55. Mechanism of the hypolipemic effect of clofibrate in postabsorptive man.
Wolfe BM; Kane JP; Havel RJ; Brewster HP
J Clin Invest; 1973 Sep; 52(9):2146-59. PubMed ID: 4353773
[TBL] [Abstract][Full Text] [Related]
56. A study of patients with atherosclerosis and renal disease with respect to lipoprotein types, fibrinolysis, and carbohydrate tolerance.
Wardle EN; Menon IS; Anderson J
Q J Med; 1972 Jan; 41(161):15-23. PubMed ID: 5070986
[No Abstract] [Full Text] [Related]
57. [Liver findings in primary hyperlipoproteinemia (HLP)].
Renger F; Hanefeld M; Jaross W; Stötzner H; Kemmer C; Leonhardt W; Trübsbach A; Schentke KU
Dtsch Z Verdau Stoffwechselkr; 1973; 33(4):199-203. PubMed ID: 4365203
[No Abstract] [Full Text] [Related]
58. [Drugs which influence plasma fatty acids and lipoproteins. Opinion of Prof. Rodolfo Paoletti].
Salvati A
Minerva Med; 1973 Sep; 64(62):3256-9. PubMed ID: 4359661
[No Abstract] [Full Text] [Related]
59. Carbohydrate metabolism in various types of hyperlipoproteinaemia.
Romics L; Stützel M; Balázsi I; Varsányi-Nagy M
Acta Med Acad Sci Hung; 1976; 33(3):225-32. PubMed ID: 1031550
[TBL] [Abstract][Full Text] [Related]
60. Insulin sensitivity after a reduced-fat diet and a monoene-enriched diet in subjects with elevated serum cholesterol and triglyceride concentrations.
Louheranta AM; Schwab US; Sarkkinen ES; Voutilainen ET; Ebeling TM; Erkkilä AT; Turpeinen AK; Uusitupa MI
Nutr Metab Cardiovasc Dis; 2000 Aug; 10(4):177-87. PubMed ID: 11079255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
